BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Joliat GR, Allemann P, Labgaa I, Demartines N, Halkic N. Treatment and outcomes of recurrent hepatocellular carcinomas. Langenbecks Arch Surg. 2017;402:737-744. [PMID: 28497194 DOI: 10.1007/s00423-017-1582-9] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.8] [Reference Citation Analysis]
Number Citing Articles
1 Wang J, Jin Z, Wu G, Wang J, Xu B, Zhu H, Guo Y, Wen Z, B S. Bioinformatics Analysis for Constructing a Six-Immune-Related Long Noncoding RNA Signature as a Prognostic Model of Hepatocellular Carcinoma. BioMed Research International 2022;2022:1-15. [DOI: 10.1155/2022/2093437] [Reference Citation Analysis]
2 Zhao QJ, Zhang J, Xu L, Liu FF. Identification of a five-long non-coding RNA signature to improve the prognosis prediction for patients with hepatocellular carcinoma. World J Gastroenterol 2018; 24(30): 3426-3439 [PMID: 30122881 DOI: 10.3748/wjg.v24.i30.3426] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 11.3] [Reference Citation Analysis]
3 Ma H, Li Z, Yuan J, Zhang L, Xie X, Yin X, Chen R, Ren Z. Extrapolating Prognostic Factors of Primary Curative Resection to Postresection Recurrences Hepatocellular Carcinoma Treatable by Radiofrequency Ablation. Gastroenterol Res Pract 2021;2021:8878417. [PMID: 33488700 DOI: 10.1155/2021/8878417] [Reference Citation Analysis]
4 Fang JZ, Xiang L, Hu YK, Yang Y, Zhu HD, Lu CD. Options for the treatment of intrahepatic recurrent hepatocellular carcinoma: Salvage liver transplantation or rehepatectomy? Clin Transplant 2020;34:e13831. [PMID: 32068916 DOI: 10.1111/ctr.13831] [Reference Citation Analysis]
5 Song ZB, Yu Y, Zhang GP, Li SQ. Genomic Instability of Mutation-Derived Gene Prognostic Signatures for Hepatocellular Carcinoma. Front Cell Dev Biol 2021;9:728574. [PMID: 34676211 DOI: 10.3389/fcell.2021.728574] [Reference Citation Analysis]
6 Joliat G, Labgaa I, Uldry E, Demartines N, Halkic N. Recurrence rate and overall survival of operated ruptured hepatocellular carcinomas. European Journal of Gastroenterology & Hepatology 2018;30:792-6. [DOI: 10.1097/meg.0000000000001115] [Cited by in Crossref: 7] [Cited by in F6Publishing: 1] [Article Influence: 1.8] [Reference Citation Analysis]
7 Murakami M, Fukumitsu N, Okumura T, Numajiri H, Murofushi K, Ohnishi K, Mizumoto M, Ishikawa H, Tsuboi K, Sakurai H. Three cases of hepatocellular carcinoma treated 4 times with proton beams. Mol Clin Oncol 2020;12:31-5. [PMID: 31814974 DOI: 10.3892/mco.2019.1950] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
8 Shan L, Jiang H, Ma L, Yu Y. Yes-associated protein: A novel molecular target for the diagnosis, treatment and prognosis of hepatocellular carcinoma. Oncol Lett 2017;14:3291-6. [PMID: 28927078 DOI: 10.3892/ol.2017.6622] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
9 Li F, Bai L, Li S, Chen Y, Xue X, Yu Z. Construction and evaluation of a prognosis lncRNA model for hepatocellular carcinoma. J Cell Biochem 2020. [PMID: 32348599 DOI: 10.1002/jcb.29608] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
10 Gou H, Liu S, Zhu G, Peng Y, Li X, Yang X, He K. Effectiveness of radiofrequency ablation versus transarterial chemoembolization for recurrent hepatocellular carcinoma: A meta-analysis. Acta Radiologica Open 2022;11:205846012210855. [DOI: 10.1177/20584601221085514] [Reference Citation Analysis]
11 Wang Z, Zhu J, Liu Y, Liu C, Wang W, Chen F, Ma L. Development and validation of a novel immune-related prognostic model in hepatocellular carcinoma. J Transl Med 2020;18:67. [PMID: 32046766 DOI: 10.1186/s12967-020-02255-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 29] [Article Influence: 10.5] [Reference Citation Analysis]
12 Chen SL, Xiao H, Xie ZL, Shen JX, Chen ZB, Wang YQ, Li B, Peng ZW, Kuang M, Lai JM, Peng S. The presence of microvascular invasion guides treatment strategy in recurrent HBV-related HCC. Eur Radiol 2020;30:3473-85. [PMID: 32048035 DOI: 10.1007/s00330-019-06640-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Yang Y, Yu H, Tan X, You Y, Liu F, Zhao T, Qi J, Li J, Feng Y, Zhu Q. Liver resection versus radiofrequency ablation for recurrent hepatocellular carcinoma: a systematic review and meta-analysis. Int J Hyperthermia 2021;38:875-86. [PMID: 34078221 DOI: 10.1080/02656736.2021.1933218] [Reference Citation Analysis]
14 Li M, Wang Z, Cao J, Han B, Zou H, Zang Y, Wu L. Risk factors and prognosis of patients with recurrent hepatocellular carcinoma who undergo liver re-resections. European Journal of Surgical Oncology 2019;45:1684-90. [DOI: 10.1016/j.ejso.2019.04.008] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
15 Zhang J, Chen J, Guan GW, Zhang T, Lu FM, Chen XM. [Expression and clinical significance of chemokine CXCL10 and its receptor CXCR3 in hepatocellular carcinoma]. Beijing Da Xue Xue Bao Yi Xue Ban 2019;51:402-8. [PMID: 31209409 DOI: 10.19723/j.issn.1671-167X.2019.03.005] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
16 Li H, Han G, Li X, Li B, Wu B, Jin H, Wu L, Wang W. MAPK-RAP1A Signaling Enriched in Hepatocellular Carcinoma Is Associated With Favorable Tumor-Infiltrating Immune Cells and Clinical Prognosis. Front Oncol 2021;11:649980. [PMID: 34178637 DOI: 10.3389/fonc.2021.649980] [Reference Citation Analysis]